Can a diabetes drug shield hearts from chemo damage?

NCT ID NCT06888505

Completed Disease control Sponsor: Hawler Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, can prevent heart damage caused by anthracycline chemotherapy. 94 adults with cancer took either dapagliflozin or a placebo daily for four months alongside their chemo. Researchers measured heart function and blood markers to see if the drug offered protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (Farxiga)
What this could lead to: If it works, this could point toward a way to protect the heart during chemotherapy, reducing the risk of long-term heart damage.
What could go wrong: This is a small, early-phase trial with only 94 participants. The results may not apply to everyone, and the drug may not provide meaningful protection in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTHRACYCLINES-INDUCED CARDIOTOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer cardiomyopathy due to anthracyclines Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTHRACYCLINES-INDUCED CARDIOTOXICITY CARDIOTOXICITY

Contacts and locations

Locations

Azadi Oncology Centre

Duhok, Duhok Governorate, 42001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.